[
  {
    "ts": "2025-08-06T16:30:00+00:00",
    "headline": "Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry",
    "summary": "Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034\" has been added to ResearchAndMarkets.com's offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to gr",
    "url": "https://finance.yahoo.com/news/cell-line-development-market-outlook-163000931.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6c27b677-fafa-3670-bc1e-618d69158123",
      "content": {
        "id": "6c27b677-fafa-3670-bc1e-618d69158123",
        "contentType": "STORY",
        "title": "Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry",
        "description": "",
        "summary": "Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034\" has been added to ResearchAndMarkets.com's offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to gr",
        "pubDate": "2025-08-06T16:30:00Z",
        "displayTime": "2025-08-06T16:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/5cf65b8d2033fb5254d931bee8c8107a",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Cell Line Development Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1YzCPghex6suEAR9aWfWgA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5cf65b8d2033fb5254d931bee8c8107a.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sz5jsJrP2UypKIooL5mpMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5cf65b8d2033fb5254d931bee8c8107a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cell-line-development-market-outlook-163000931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cell-line-development-market-outlook-163000931.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "1548.HK"
            },
            {
              "symbol": "SRT.DE"
            },
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T12:08:10+00:00",
    "headline": "Bio-Techne beats quarterly estimates, flags tariff uncertainty for customers",
    "summary": "(Reuters) -Bio-Techne on Wednesday said it expects uncertainty related to U.S. President Donald Trump's tariff and academic funding policies to spill into its fiscal year 2026 and could create pressure on the company's performance.  \"We expect low single-digit growth until there is more certainty around various administration policies out there on academic funding, pharmaceutical tariffs and MFN (most favored nation) pricing,\" Chief Financial Officer Jim Hippel said on an investor call.  Significant cuts to U.S. academic research, along with potential tariffs for the pharmaceutical sector and the proposed MFN drug pricing model, have introduced a sense of uncertainty across the company's healthcare clients.",
    "url": "https://ca.finance.yahoo.com/news/bio-techne-beats-quarterly-estimates-120810709.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "039d986b-2a15-3d8e-a1ac-d85fecbcb433",
      "content": {
        "id": "039d986b-2a15-3d8e-a1ac-d85fecbcb433",
        "contentType": "STORY",
        "title": "Bio-Techne beats quarterly estimates, flags tariff uncertainty for customers",
        "description": "",
        "summary": "(Reuters) -Bio-Techne on Wednesday said it expects uncertainty related to U.S. President Donald Trump's tariff and academic funding policies to spill into its fiscal year 2026 and could create pressure on the company's performance.  \"We expect low single-digit growth until there is more certainty around various administration policies out there on academic funding, pharmaceutical tariffs and MFN (most favored nation) pricing,\" Chief Financial Officer Jim Hippel said on an investor call.  Significant cuts to U.S. academic research, along with potential tariffs for the pharmaceutical sector and the proposed MFN drug pricing model, have introduced a sense of uncertainty across the company's healthcare clients.",
        "pubDate": "2025-08-06T12:08:10Z",
        "displayTime": "2025-08-06T12:08:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/bio-techne-beats-quarterly-estimates-120810709.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-beats-quarterly-estimates-120810709.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            },
            {
              "symbol": "DHR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-06T12:07:05+00:00",
    "headline": "Here’s Why Kovitz Core Equity Strategy Increased Its Position in Thermo Fisher Scientific (TMO)",
    "summary": "Kovitz Investment Group Partners, LLC, an investment management company, released its “Kovitz Core Equity Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy returned 7.9% compared to the S&P 500’s 10.9% return. Equity markets saw notable volatility after the President’s “Liberation Day” tariff announcement […]",
    "url": "https://finance.yahoo.com/news/why-kovitz-core-equity-strategy-120705021.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "77f4bfad-07f2-3e32-8e3b-dcd82301c340",
      "content": {
        "id": "77f4bfad-07f2-3e32-8e3b-dcd82301c340",
        "contentType": "STORY",
        "title": "Here’s Why Kovitz Core Equity Strategy Increased Its Position in Thermo Fisher Scientific (TMO)",
        "description": "",
        "summary": "Kovitz Investment Group Partners, LLC, an investment management company, released its “Kovitz Core Equity Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy returned 7.9% compared to the S&P 500’s 10.9% return. Equity markets saw notable volatility after the President’s “Liberation Day” tariff announcement […]",
        "pubDate": "2025-08-06T12:07:05Z",
        "displayTime": "2025-08-06T12:07:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Thermo Fisher Scientific’s (TMO) Dividend: Steady Payouts in a Growing Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t09qF4JVyCHBUYhbTpriVA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/anwOpxdO_.7889BHm6WJ1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4505f322faedfbfafb576fe4b20bd921.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-kovitz-core-equity-strategy-120705021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-kovitz-core-equity-strategy-120705021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]